News & Updates
Filter by Specialty:
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
12 Oct 2022
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022
Telmisartan does not deliver in peripheral arterial disease
Treatment with the angiotensin receptor blocker telmisartan does not appear to confer improvements on walking performance in patients with lower extremity peripheral artery disease (PAD), according to the TELEX trial.
Telmisartan does not deliver in peripheral arterial disease
11 Oct 2022
Osimertinib plus selumetinib shows promise in advanced NSCLC
The combination of osimertinib plus selumetinib exhibits antitumour activity in patients with MET-negative, EGFRm advanced nonsmall cell lung cancer (NSCLC), with the safety profile consistent with the reported safety data for the drugs, according to data from the small open-label, phase Ib study.
Osimertinib plus selumetinib shows promise in advanced NSCLC
11 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.